Preview

Атеротромбоз

Расширенный поиск

ПРИМЕНЕНИЕ АЦЕТИЛСАЛИЦИЛОВОЙ КИСЛОТЫ У КАРДИОЛОГИЧЕСКИХ БОЛЬНЫХ: СУЩЕСТВУЮЩИЕ ПРОБЛЕМЫ И НОВЫЕ ПОКАЗАНИЯ

https://doi.org/10.21518/2307-1109-2014-1-5-21

Полный текст:

Аннотация

.

Об авторе

П. С. Лагута
НИИ клинической кардиологии им. А. Л. Мясникова ФГБУ РКНПК МЗ РФ
Россия


Список литературы

1. Campbell CL, Smyth S. et. al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA, 2007;297:2018–24.

2. Morita I., Schindler M. et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and –2. J. Biol. Chem., 1995;270:10902–8.

3. Smith WL. Prostanoid biosynthesis and the mechanism of action. Am. J. Physiol., 1992;263; F118-F191.

4. Hinz B, Brune K. Cyclooxygenase-2–10 years later. JPET, 2002;300:367–375.

5. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Ann. Rev. Pharmacol. Toxicol., 1998;38:97–120.

6. Patrono C. et al. Platelet-Active Drugs: The Relationships among dose, effectiveness, and side effects. The Seventh ACCP Conference of Antithrombotic and Thrombolytic Therapy 2004. Chest, 2004;126:234s-264s.

7. Eikelboom JW, Hirsh J. et al. Antiplatelet Drugs. Antithrombotic therapy and prevention of thrombosis, 9th ACCP Evidence – based Clinical Practice Guidelines. Chest, 2012;141 (2):89s-119s.

8. Clarke RJ, Mayo G. et al. Suppression of thromboxane A2 but not systemic prostacyclin by controlled-release aspirin. N. Engl. J. Med., 1991;325:1137–41.

9. McAdam BF, Catella-Lawson F. et al. Systemic biosynthesis of prostacyclin by cyclooxygenase-2: the human pharmacology of a selective inhibitor of cyclooxygenase-2. Proc. Natl. Acad. Sci. USA, 1999;96:272–77.

10. Reilly IAG, FitzGerald GA. Aspirin in cardiovascular disease. 1988;35:154–76.

11. Kearney P, Baigent C, Godwin J. et al. Do selective cyclo-oxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. Br. Med. J., 2006;332:1302–8.

12. McConnel H. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J., 2002;324:71–86.

13. Pedersen AK, FitzGeralg GA. Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N. Engl. J. Med., 1984;311:1206–11.

14. Juul-Moller S, Edvardsson N, Jahnmatz B. et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients in patients with stable chronic angina pectoris. Lancet, 1992;340: 421–5.

15. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISK Group. Lancet, 1990;336:827–30.

16. The SALT Collaborative Group. Swedish Aspirin Low Dose Trial (SALT) of 75 mg aspirin in secondary prophylaxis after cerebrovascular ischaemic events. Lancet, 1991;338:1345–9.

17. Lindblad B, Persson NH. et al. Does low dose acetylsalicylic acid prevent stroke after carotid surgery? Stroke, 1993;24 (8):1125–8.

18. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N. Engl. J. Med., 1991;325:1261–66.

19. Taylor DW, Barnett HJM. et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: randomised controlled trial. Lancet, 1999;353:2179–83.

20. Mangano D. T. Aspirin and mortality from coronary bypass surgery. N. Engl. J. Med., 2002;347:1309–17.

21. Vandvik O, Lincoff AM. et al. Primary and secondary prevention of cardiovascular disease. Antithrombotic therapy and prevention of thrombosis, 9th ACCP Evidence – based Clinical Practice Guidelines. Chest, 2012;141 (2):637s-668s.

22. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation. The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation of the European Society of Cardiology. Eur. Heart J., 2011;32:2999–3054.

23. OGara PT, Kushner FG, Ascheim DD. et al. 2013 ACCF/AHA Guideline for the management of patients ST elevation myocardial infarction. Journal of the American College of Cardiology, 2013;61:78–140.

24. Antithrombotic Trialists (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 2009;373:1849–60.

25. Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Commitee of the Physicians’ Health Study Research Group. N. Engl. J. Med., 1989;321:129–35.

26. Peto R, Gray R, Collins R. et al. Randomized trial of prophylactic daily aspirin in British male doctors. Br. Med. J., 1988;296:313–6.

27. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet, 1998;351:233–41.

28. Hansson L, Zanchetti A, Carruthers S. G. et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of Hypertension Optimal Treatment (HOT) randomized trial. Lancet, 1988;351:1766–62.

29. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet, 2001;357:89–95.

30. Ridker P, Cook N, Min Lee L. et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med., 2005;352.

31. Seshasai SRK, Wijesuriya S, Sivakumaran R. et al. Effect of aspirin on vascular and non-vascular outcomes: meta-analysis of randomised controlled trials. Arch Intern Med, 2012;172 (3):209–16.

32. Ogawa H, Nakayama M, Morimoto T. et al. Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Lowdose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008;300 (18):2134–41.

33. Belch J, MacCuish A, Campbell et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br. Med. J., 2008;337: a1840.

34. Fowkes FG, Price JF, Stewart MC. et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA, 2010;303 (9):841–8.

35. Rothwell PM, Price JF et al. Short-term effects of daily aspirin on cancer incidence, mortality, and nonvascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet, 2012;379:1602–12.

36. Rothwell PM, Fowkes FGR et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patients data from randomized trials. Lancet, 2011;377:31–41.

37. Jacobs EJ, Newton CC, et al. Daily aspirin use and cancer mortality in large US cohort. J. Natl. Cancer Inst., 2012;104:10p.

38. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur. Heart J., 2012;33:1635–1701.

39. Centers for Disease Control and Prevention. Nationa; Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007, Atlanta, US Department of Health and Human Services, Centers for Disease Control and Prevention., 2008.

40. Buse JB, Ginsberg HN, Bakris GL. et al. Primary prevention of cardiovascular Disease in people with diabetes mellitus: a scientific statement from American Heart Association and The American Diabetes Association. Circulation, 2007;115:114–26.

41. Pignone M, Alberts MJ, Colwell JA. Aspirin for Primary Prevention of Cardiovascular Events in people with diabetes. Circulation, 2010;121:2694–2701.

42. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. ETDRS Investigators. JAMA, 1992;268:1292–1300.

43. Pearson TA, Blair SN. et. al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patient without Coronary or other Atherosclerotic Vascular Diseases. Circulation, 2002;106:388–91.

44. Well J, Colin-Jones D. et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br. Med. J., 1995;310:827–30.

45. Garcia Rodriguez LA, Cattaruzzi C. et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal and anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch. Intern Med, 1998;158:33–9.

46. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Am. J. Gastroent., 1998;93:2037–46.

47. Chan FK, Chung SC. et al. Preventing recurrent upper gastrointestinal bleeding in patient with Helicobacter pylori infection who are taken low dose aspirin or naproxen. N. Engl. J. Med., 2001;344:967–73.

48. Lai KC, Lam SK. et. al Lansoprazole for the prevention of recurrences of ulcer complications from long term low dose aspirin use. N. Engl. J. Med., 2002;346:2033–8.

49. McKee SA, Sane DS, Deliargyris EN. Aspirin Resistance in Cardiovascular Disease: A Review of Prevalence, Mechanisms, and Clinical Significance. Thromb Haemost., 2002;88:711–5.

50. Patrono C.: Aspirin resistance. definition, mechanism and clinical read-outs. J. Thromb Haemost, 2003;1:1710–13.

51. Snoep JD, Hovens MM. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern Med, 2007;167:1593–9.

52. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation, 2002;105:1650-5.

53. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. JACC, 2003;41:961-5.

54. Lordkipanidze M, Pharand C, Schampaer E. et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patient with stable coronary artery disease. Eur Hear J, 2007;28:1702–8.

55. Kuliczkowski W, Witkowski A. et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drug resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur. Heart J., 2009;30:426–35.

56. Naess IA, Christiansen SC. et al. Incidence and mortality of venous thrombosis: a population based study. J. Thromb. Haemost., 2007;5:692–9.

57. Kearon C., Akl EA. et al. Antithrombotic therapy for VTE disease. Antithrombotic therapy and prevention of thrombosis, 9th ACCP Evidence – based Clinical Practice Guidelines. Chest, 2012;141 (2):419s-494s.

58. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet, 2000;355:1295–1302.

59. Grady D, Wenger NK, Herrington D. et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med, 2000;132:689–96.

60. The ESPS 2 Group. European Stroke Prevention Study 2. Efficacy and safety data. Secondary endpoints. J Neurol Sci., 1997;151: S27-S37.

61. Becattini C, Agnelli G, Schenone A. et al. Aspirin for preventing the recurrence of venous thromboembolism. N. Engl. J. Med, 2012;366:1959–67.

62. Brighton TA, Eikelboom JW et al. Low-dose aspirin for preventing the recurrent venous thromboembolism. N. Engl. J. Med, 2012; Nov 4. NEJM.org.


Для цитирования:


Лагута П.С. ПРИМЕНЕНИЕ АЦЕТИЛСАЛИЦИЛОВОЙ КИСЛОТЫ У КАРДИОЛОГИЧЕСКИХ БОЛЬНЫХ: СУЩЕСТВУЮЩИЕ ПРОБЛЕМЫ И НОВЫЕ ПОКАЗАНИЯ. Атеротромбоз. 2014;(1):5-21. https://doi.org/10.21518/2307-1109-2014-1-5-21

For citation:


Лагута П.С. . Atherothrombosis. 2014;(1):5-21. (In Russ.) https://doi.org/10.21518/2307-1109-2014-1-5-21

Просмотров: 318


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)